8-K: Mobia Medical Appoints New Director, Expands Board

Mobia Medical, Inc. has expanded its Board of Directors to seven members with the appointment of Dr. Reza Zadno, who will also serve on the Compensation Committee.

Summary

• Mobia Medical, Inc. announced on July 14, 2026, that its Board of Directors has been expanded from six to seven members.
• Dr. Reza Zadno has been appointed as a new Class III director, with his term set to expire at the 2029 annual meeting of stockholders.
• Dr. Zadno will also serve as a member of the Board's Compensation Committee.
• The Board has determined that Dr. Zadno meets the independence requirements for both the Board and the Compensation Committee.
• In connection with this appointment, Dr. William Harrington resigned from the Compensation Committee.
• Dr. Zadno brings extensive experience from leadership roles at PROCEPT BioRobotics Corporation and Avedro, Inc., as well as board experience with other medical and biopharmaceutical companies.
• He also serves as an Operating Partner at Jolt Capital and a Special Advisor to the American Academy of Ophthalmology.
• Dr. Zadno's appointment is not based on any arrangement with other persons, and there are no reportable transactions between him and Mobia Medical.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, reflecting a strengthening of the board's expertise and governance structure without immediate financial implications.

Positives

• Expansion of the Board of Directors with the addition of a highly experienced individual, Dr. Reza Zadno.
• Dr. Zadno's appointment to the Compensation Committee enhances the committee's expertise.
• Dr. Zadno is deemed an independent director, aligning with good corporate governance practices.
• Dr. Zadno's background includes significant leadership and board experience in the medical technology and biopharmaceutical sectors.

Negatives

• Resignation of Dr. William Harrington from the Compensation Committee.

Risks

• Potential challenges in integrating a new director with the existing board dynamics.
• The effectiveness of Dr. Zadno's contributions to the Compensation Committee and overall board strategy remains to be seen.

Future Outlook

No specific forward-looking statements or financial guidance were provided in this filing.

Management Comments

• The Board of Directors increased the size of the Board from six to seven members and appointed Reza Zadno, Ph.D. as a new member of the Board.
• Dr. Zadno was appointed as a Class III director, with a term expiring at Mobia's 2029 annual meeting of stockholders or until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
• The Board also appointed Dr. Zadno to serve as a member of the Compensation Committee of the Board.
• The Board determined that Dr. Zadno qualifies as an independent director and satisfies the requirements to serve on the Compensation Committee.
• In connection with his appointment, Dr. William Harrington resigned as a member of the Compensation Committee.

Industry Context

StockSavvy.ai notes that the appointment of experienced directors, particularly those with a background in surgical robotics and ophthalmology, is a common strategy for medical technology companies like Mobia Medical to enhance strategic oversight and governance as they navigate industry advancements and competitive landscapes.

Management Changes

Corporate Governance

Related Party Transactions

• There are no transactions between Dr. Zadno and Mobia that would be required to be reported under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: The addition of an experienced director may be viewed positively, potentially enhancing strategic oversight and governance.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Dr. Zadno will receive compensation as a non-employee director in accordance with Mobia's program.
• Mobia expects to enter into its standard form of indemnification agreement with Dr. Zadno.

Key Dates

Keywords

Mobia Medical, Board of Directors, Director Appointment, Compensation Committee, Corporate Governance, Reza Zadno, Medical Devices, Biotechnology